RxDoctor Payments Data

Daniel Smith, MD

Infectious Disease · Dyer, INNPI 1396705430

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Viiv Healthcare Company at 27.6% of the total. Reporting peaked in 2019 at $635 and has fallen 95.8% since, to $27 in 2025.

$1,432in general payments, 2019–2025

Across 90 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$395
  • Gilead$233
  • Smith+Nephew$137
  • AbbVie$120
  • Tactile Systems Technology Inc$75
  • Merck$67
  • plus $405 from 14 others

What the payments were for

  • Food & beverage$1,432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,432 in reported general payments places this provider in the 75th percentile of 152 infectious disease providers in Indiana.

See all infectious disease providers in Indiana

Medicare billing

Part B allowed, 2024
$119,949
Medicare patients
262
Services billed
1,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala45$176,122
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf22$110,304
TivicayDolutegravir Sodium36$93,564
DescovyEmtricitabine/Tenofov Alafenam23$58,732
DovatoDolutegravir Sodium/Lamivudine19$56,709
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df34$30,042
TruvadaEmtricitabine/Tenofovir (Tdf)12$21,753
ReyatazAtazanavir Sulfate12$17,114
Darunavir11$11,606
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam24$9,200
VascepaIcosapent Ethyl20$7,441
Vancomycin Hcl42$7,299
Emtricitabine11$5,083
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav209$3,800
NorvirRitonavir12$3,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Truvada$233$256,60680 claims
Viiv Healthcare CompanyTivicay, Dovato$395$150,27455 claims
AbbVieNorvir$120$3,03512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 infectious disease providers in Indiana.

Other infectious disease in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →